

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### Independent Auditors' Report

To

The Members

#### **ARUNJYOTI BIO VENTURES LIMITED**

Report on the Audit of the Standalone Financial Statements

#### **Opinion**

We have audited the accompanying standalone financial statements of Arunjyothi Bio Ventures Limited, which comprise the Balance Sheet as at 31st March, 2021, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the Profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

#### **Basis for opinion**

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

---

## ARUNJYOTI BIO VENTURES LIMITED

---

### **Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

### **Information Other than the Standalone Financial Statements and Auditor's Report Thereon**

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating

---

## ARUNJYOTI BIO VENTURES LIMITED

---

effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

### Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has

---

## ARUNJYOTI BIO VENTURES LIMITED

---

adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure- A" a statement on the matters specified in paragraphs 3 and 4 of the order.
2. As required by Section 143(3) of the Act, based on our audit we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.
  - d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.
  - e) On the basis of the written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
  - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure- B".
  - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

---

---

**ARUNJYOTI BIO VENTURES LIMITED**

---

---

- i. The Company does not have any pending litigations on its financial position in its standalone financial Statements.
- ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.
- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the company.

**For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No.:006492S**

**Sd/-  
D Ramesh Kumar  
Partner  
Membership No.217139**

**Place: Hyderabad  
Date: 26.06.2021**

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### **Annexure “B” to the Independent Auditor’s Report**

(Referred to in paragraph 1(f) under ‘Report on Other Legal and Regulatory Requirements’ section of our report to the Members of Arunjyothi Bio Ventures Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of ArunJyothi Bio Ventures Limited (“the Company”) as of March 31, 2021 in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The Management of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditor’s Responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and

---

## ARUNJYOTI BIO VENTURES LIMITED

---

their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

---

---

## **ARUNJYOTI BIO VENTURES LIMITED**

---

---

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No.:006492S**

**Sd/-  
D Ramesh Kumar  
Partner  
Membership No.217139**

**Place: Hyderabad  
Date: 26.06.2021**

## ARUNJYOTI BIO VENTURES LIMITED

Financial Position as at March 31, 2021

(Amt. in Rs.)

	Particulars	Note No.	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
I	<b>ASSETS</b>				
1	<b>Non-current assets</b>				
	(a) Property, plant and equipment	3	-	-	-
	(b) Right to use assets		-	-	-
	(c) Capital work in progress		-	-	-
	(d) Investment properties		-	-	-
	(e) Good will		-	-	-
	(f) Other intangible Assets		-	-	-
	(g) Intangible Assets under Development		-	-	-
	(h) Biological Assets other than Bearer Plants		-	-	-
	(d) Financial assets		-	-	-
	(i) Investments	4	-	-	-
	(ii) Trade receivables	5	-	-	-
	(iii) Loans	6	1,49,71,192	1,49,71,192	1,49,71,192
	(e) Deferred Tax Asset (Net)	7	-	-	-
	(f) Other non-current asset	8	-	-	-
	<b>Total non-current assets (A)</b>		<b>1,49,71,192</b>	<b>1,49,71,192</b>	<b>1,49,71,192</b>
2	<b>Current assets</b>				
	(a) Inventories	9	2,59,478	2,96,484	52,89,553
	(a) Financial assets				
	(i) Investments	4	-	-	-
	(ii) Trade receivables	5	1,83,81,369	2,67,25,481	2,35,59,851
	(iii) Cash and cash equivalents	10	80,87,045	1,11,76,399	34,58,225
	(iv) Bank Balances other than (iii) above		-	-	-
	(b) Current Tax Asset (Net)	7	-	-	-
	(c) Other current assets	11	53,33,981	58,24,519	75,59,658
	<b>Total current assets (B)</b>		<b>3,20,61,873</b>	<b>4,40,22,882</b>	<b>3,98,67,287</b>
	Non Current Assets Clasified as Held for Sale (C)	11.1	-	-	-
	<b>Total assets (A+B+C)</b>		<b>4,70,33,065</b>	<b>5,89,94,074</b>	<b>5,48,38,479</b>
II	<b>EQUITY AND LIABILITIES</b>				
1	<b>Equity</b>				
	(a) Equity share capital	12	2,07,09,000	2,07,09,000	2,07,09,000
	(b) Other equity	12.1	(12,57,727)	(19,43,028)	(30,50,205)
	<b>Total equity (A)</b>		<b>1,94,51,274</b>	<b>1,87,65,972</b>	<b>1,76,58,795</b>
2	<b>Liabilities</b>				
(i)	<b>Non-current liabilities</b>				
	(a) Financial Liabilities				
	(i) Borrowings	13	-	-	-
	(ii) Trade Payables	14	-	-	-
	(iii) Other Financial Liabilities	15	-	-	-
	(b) Long term provisions	16	-	-	-
	(c) Deferred tax Liabilities(Net)	7	-	-	-
	(d) Other non Current Liabilities		-	-	-
	<b>Total non-current liabilities (B)</b>			-	-
(ii)	<b>Current liabilities</b>				
	(a) Financial liabilities				
	(i) Borrowings	13	-	-	-
	(ii) Trade payables	14	1,31,03,211	2,18,42,239	2,10,57,322
	(iii) Other financial liabilities	15	-	-	-
	(b) Short term provisions	16	2,39,838	2,51,860	84,319
	(c) Other current liabilities	17	1,42,38,743	1,81,34,003	1,59,88,043
	(d) Current Tax Liabilities (net)	7	-	-	-
	<b>Total current liabilities (C)</b>		<b>2,75,81,792</b>	<b>4,02,28,102</b>	<b>3,71,29,684</b>
	<b>Total liabilities (D=B+C)</b>		<b>2,75,81,792</b>	<b>4,02,28,102</b>	<b>3,71,29,684</b>
	<b>Total equity and liabilities (A+D)</b>		<b>4,70,33,065</b>	<b>5,89,94,074</b>	<b>5,47,88,479</b>

The notes are an integral part of the financial statements

For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No:006492S

Ramesh Kumar D  
Partner  
Membership No: 217139  
UDIN: 21217139AAAAFA4442

Place: Hyderabad  
Date : 26.06.2021

For and on behalf of the Board of Directors  
Arunjyoti Bio Ventures Limited

Sd/-  
Pabbathi Praveen Kumar  
Wholetime Director & CFO  
DIN:02009879

Sd/-  
Babulal Raja Kumar  
Wholetime Director  
DIN:07529064

Sd/-  
Swati Jain  
Company Secretary & Compliance Officer

## ARUNJYOTI BIO VENTURES LIMITED

### Provisional Statement of Profit and Loss and Other Comprehensive Income for the Year ended Mar 31, 2021

(Amt. in Rs.)

	Note No.	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
<b>I Continuing Operations</b>				
Revenue from operations	18	5,51,28,875	7,30,88,613	3,71,74,710
Other income	19	18,263	25,745	15,627
Net gain on de-recognition of financial assets at amortised cost	20	-	-	-
Net gain on reclassification of financial assets	21	-	-	-
<b>Total income</b>		<b>5,51,47,138</b>	<b>7,31,14,358</b>	<b>3,71,90,337</b>
<b>VI Expenses</b>				
(a) Cost of material Consumed	22	4,66,72,019	6,08,97,004	3,14,23,627
(b) Purchase of Stock in Trade		-	-	-
(c) Changes in stock of finished goods, work-in progress and stock-in-trade	23	-	-	-
(d) Direct Expenses	24	14,68,542	-	-
(d) Employee benefits	25	23,79,000	31,34,506	43,00,133
(e) Finance cost	26	15,704	1,929	1,431
(f) Depreciation expense	27	-	-	-
(g) Impairment expenses/losses		-	-	-
(h) Net loss on de-recognition of financial assets at amortized cost	20	-	-	-
(i) Net loss on reclassification of financial assets	21	-	-	-
(c) Other expenses	28	36,89,422	77,71,883	10,76,898
<b>Total expenses (VI)</b>		<b>5,42,24,686</b>	<b>7,18,05,322</b>	<b>3,68,02,089</b>
<b>VII Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)</b>		<b>9,22,451</b>	<b>13,09,036</b>	<b>3,88,248</b>
<b>VIII Share of profit/(loss) of associates</b>				
Share of profit/(loss) of joint ventures				
<b>IX Profit/(Loss) before exceptional items and tax</b>		<b>9,22,451</b>	<b>13,09,036</b>	<b>3,88,248</b>
<b>X Exceptional itmes</b>				
<b>XI Profit before Tax</b>		<b>9,22,451</b>	<b>13,09,036</b>	<b>3,88,248</b>
<b>XII Tax expense :</b>				
a. Current tax		2,39,838	2,59,461	84,319
b. Deferred tax		-	(7,602)	(84,319)
<b>XIII Profit/(loss) for the year from continuing operations (XI-XII)</b>		<b>6,82,613</b>	<b>10,57,177</b>	<b>3,88,248</b>
<b>Discontinued Operations</b>				
Profit/(loss) from discontinued operations		-	-	-
Tax Expense of discontinued operations		-	-	-
<b>XVI Profit/(loss) from discontinued operations (XIV +XV)</b>				
<b>XVII Profit/(loss) for the year (XIII+XVI)</b>		<b>6,82,613</b>	<b>10,57,177</b>	<b>3,88,248</b>
<b>XIX Other comprehensive income(OCI)</b>				
<b>A (i) Items that will not be recycled to profit or loss</b>				
<b>B (i) Items that may be reclassified to profit or loss</b>		-	-	-
<b>Total other comprehensive income</b>		<b>-</b>	<b>-</b>	<b>-</b>
<b>IX. Total comprehensive income for the year (V+ VI)</b>		<b>6,82,613</b>	<b>10,57,177</b>	<b>3,88,248</b>
<b>X. Earning per equity share (for Continuing Opertations)</b>				
(i) Basic		0.33	0.51	0.19
(ii) Diluted.		0.33	0.51	0.19
<b>XI. Earnings per equity share (for discontinued operation):</b>				
(i) Basic		-	-	-
(ii) Diluted.		-	-	-
<b>XII. Earnings per equity share (for Continued and discontinued operation):</b>				
(i) Basic		0.33	0.51	0.19
(ii) Diluted.		0.33	0.51	0.19

The notes are an integral part of the financial statements

For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No:006492S

Ramesh Kumar D  
Partner  
Membership No: 217139  
UDIN: 21217139AAAAFA4442

Place: Hyderabad  
Date : 26.06.2021

For and on behalf of the Board of Directors  
Arunjyoti Bio Ventures Limited

Sd/-  
Pabbathi Praveen Kumar  
Wholetime Director & CFO  
DIN:02009879

Sd/-  
Babulal Raja Kumar  
Wholetime Director  
DIN:07529064

Sd/-  
Swati Jain  
Company Secretary & Compliance Officer

# ARUNJYOTI BIO VENTURES LIMITED

## CASH FLOW STATEMENT FOR THE YEAR ENDED 31.03.2021

	As at Mar 31, 2021	As at Mar 31, 2020	(Amt. in Rs.) As at March 31, 2019
<b>A CASH FROM OPERATING ACTIVITIES</b>			
(Loss)/Profit before tax and extraordinary items	9,22,451	13,09,036	3,88,248
<b>Adjustment for:</b>			
Income tax expense recognised in profit or loss	-	-	-
Finance costs recognised in profit or loss	-	-	-
Investment income recognised in profit or loss	-	-	-
Gain on disposal of property, plant and equipment	-	-	-
Gain on disposal of a subsidiary	-	-	-
Gain on disposal of interest in former associate	-	-	-
Net (gain)/loss recorded in profit or loss on financial liabilities designated as at fair value through profit or loss	-	-	-
Net (gain)/loss arising on financial assets mandatorily measured at fair value through profit or loss	-	-	-
Net loss/(gain) arising held for trading financial liabilities	-	-	-
Hedge ineffectiveness on cash flow hedges	-	-	-
Net (gain)/loss on disposal of available-for-sale financial assets	-	-	-
Impairment loss recognised on trade receivables	-	-	-
Reversal of impairment loss on trade receivables	-	-	-
Depreciation and amortisation of non-current assets	-	-	-
Transfers from Profit & Loss	-	-	-
Net foreign exchange (gain)/loss	-	-	-
Expense recognised in respect of equity-settled share-based payments	-	-	-
Expense recognised in respect of shares issued in exchange for goods/services	-	-	-
Amortisation of financial guarantee contracts	-	-	-
<b>Operating Profit before Working Capital Changes</b>	<b>9,22,451</b>	<b>13,09,036</b>	<b>3,88,248</b>
<b>Movement for Working Capital:</b>			
Increase in trade and other receivables	83,44,112	(31,65,630)	2,15,72,421
(Increase)/decrease in amounts due from customers under construction contracts	-	-	-
(Increase)/decrease in inventories	37,006	49,93,069	(52,89,553)
(Increase)/decrease in other assets	4,90,538	17,80,849	(54,217)
Decrease in trade and other payables	(87,39,028)	7,84,918	(4,90,76,170)
Increase/(decrease) in amounts due to customers under construction contracts	-	-	-
Increase/(decrease) in provisions	(12,022)	2,04,000	(1,18,201.00)
(Decrease)/increase in deferred revenue	-	-	-
(Decrease)/increase in other liabilities	(38,95,260)	21,45,959	26,74,176
<b>Changes in non current assets and liabilities</b>			
Decrease/(Increase) in loans & advances	-	-	27,85,122
Decrease/(Increase) in Long Term Provisions	-	-	-
Decrease/(Increase) in Other non Current Assets	-	-	-
<b>Cash generated from operations</b>	<b>(28,52,204)</b>	<b>80,52,201</b>	<b>(2,71,18,174)</b>
- Income taxes paid	(2,64,463)	(3,34,028)	-
<b>Net Cash flow before extraordinary items</b>	<b>(31,16,667)</b>	<b>77,18,173</b>	<b>(2,71,18,174)</b>
- Extraordinary & Prior period items	-	-	-
<b>NET CASH FROM OPERATING ACTIVITIES</b>	<b>(31,16,667)</b>	<b>77,18,173</b>	<b>(2,71,18,174)</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES:</b>			
Payments to acquire financial assets	-	-	-
Proceeds on sale of financial assets	-	-	-
Interest received	-	-	-
Royalties and other investment income received	-	-	-
Dividends received from associates	-	-	-
Other dividends received	-	-	-
Amounts advanced to related parties	-	-	-
Repayments by related parties	-	-	-
Payments for property, plant and equipment	-	-	-
Proceeds from disposal of property, plant and equipment	-	-	-
Payments for investment property	-	-	-
Proceeds from disposal of investment property	-	-	-
Payments for intangible assets	-	-	-
Net cash outflow on acquisition of subsidiaries	-	-	-
Net cash inflow on disposal of subsidiary	-	-	-
Net cash inflow on disposal of associate	-	-	-
<b>NET CASH FROM INVESTING ACTIVITIES</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from issue of equity instruments of the Company	-	-	-
Proceeds from issue of convertible notes	-	-	-
Payment for share issue costs	-	-	-
Payment for buy-back of shares	-	-	-
Payment for share buy-back costs	-	-	-
Proceeds from issue of redeemable preference shares	-	-	-
Proceeds from issue of perpetual notes	-	-	-
Payment for debt issue costs	-	-	-
Proceeds from borrowings	-	-	(19,34,999)
Proceeds from government loans	-	-	-
Proceeds on disposal of partial interest in a subsidiary that does not involve loss of control	-	-	-
Dividends paid on redeemable cumulative preference shares	-	-	-
Dividends paid to owners of the Company	-	-	-
Interest paid	-	-	-
Long Term Provisions	-	-	-
<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>-</b>	<b>-</b>	<b>(19,34,999)</b>
<b>NET INCREASE IN CASH &amp; CASH EQUIVALENTS</b>	<b>(31,16,667)</b>	<b>77,18,173</b>	<b>(2,90,53,173)</b>
<b>Cash and cash equivalents at the beginning of the year 1.04.2020</b>	<b>1,11,76,398</b>	<b>34,08,225</b>	<b>3,24,61,398</b>
Effects of exchange rate changes on the balance of cash held in foreign currencies	-	-	-
<b>Cash and cash equivalents at the end of the year as on 31.03.2021</b>	<b>80,59,731</b>	<b>1,11,26,398</b>	<b>34,08,225</b>
<b>Reconciliation of cash and cash equivalents as per the cash flow Statement</b>			
Cash and cash equivalents (Note-10.1)	80,87,045	1,11,76,399	34,58,225
Bank overdraft	-	-	-
<b>Balance as per statement of cash flows</b>	<b>80,87,045</b>	<b>1,11,76,399</b>	<b>34,58,225</b>

For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No:006492S

Ramesh Kumar D  
Partner  
Membership No: 217139  
UDIN: 21217139AAAAFA4442

Place: Hyderabad  
Date : 26.06.2021

For and on behalf of the Board of Directors  
Arunjyoti Bio Ventures Limited

Sd/-  
Pabbathi Praveen Kumar  
Wholtime Director & CFO  
DIN:02009879

Sd/-  
Babulal Raja Kumar  
Wholtime Director  
DIN:07529064

Sd/-  
Swati Jain  
Company Secretary & Compliance Officer

## ARUNJYOTI BIO VENTURES LIMITED

Statement of Changes in Equity For the year ended 31 March 2021

a. Equity share capital

(Amount in Rs.)

	Amount
Balance as at the 1 April 2019	2,07,09,000
Changes in equity share capital during 2019-20	-
Balance as at the 31 March 2020	2,07,09,000
Changes in equity share capital during 2020-21	-
Balance as at the 31 March 2021	2,07,09,000

b. Other equity

(Amount in Rs.)

Particulars	Reserves and surplus			Items of Other comprehensive income (OCI)	Total
	Capital Reserve	Securities Premium	Retained earnings	Others	
Balance at 1 April 2019	23,33,750	-	(53,83,955)	-	(30,50,205)
Total comprehensive income for the year ended 31 March 2019					
Profit or loss	-		10,57,177	-	10,57,177
Other comprehensive income/net of tax			-	-	-
Total comprehensive income	-		10,57,177	-	10,57,177
Transactions with owners in their capacity as owners directly in equity	-		-	-	-
Balance at 31 March 2020	23,33,750	-	(43,26,778)	-	(19,93,028)
Total comprehensive income for the year ended 31 March 2020					
Profit or loss	-		6,82,613	-	6,82,613
Other comprehensive income/net of tax	-		-	-	-
Total comprehensive income	-		6,82,613	-	6,82,613
Transactions with owners in their capacity as owners	-		-	-	-
Balance at 31 March 2021	23,33,750	-	(36,44,165)	-	(13,10,415)

For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No:006492S

Ramesh Kumar D  
Partner  
Membership No: 217139  
UDIN: 21217139AAAF4442

Place: Hyderabad  
Date : 26.06.2021

For and on behalf of the Board of Directors  
Arunjyoti Bio Ventures Limited

Sd/-  
Pabbathi Praveen Kumar  
Wholetime Director & CFO  
DIN:02009879

Sd/-  
Babulal Raja Kumar  
Wholetime Director  
DIN:07529064

Sd/-  
Swati Jain  
Company Secretary & Compliance Officer

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### Corporate Information:

ARUNJYOTI BIO VENTURES LIMITED ("the Company") was incorporated in India in the year 1986 having its Registered office at Plot No. 45, P & T Colony, Karkhana, Secunderabad, Hyderabad, TG 500009 In.

### Disclosure of Significant Accounting Policies:

#### 1. Basis for Preparation of Financial Statements:

##### a) Compliance with Indian Accounting Standards (Ind AS)

The Ind AS financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The Ind AS financial statements have been prepared on the historical cost basis except for certain instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Accordingly, the Company has prepared these Financial Statements which comprise the Balance Sheet as at 31 March, 2021, the Statement of Profit and Loss for the year ended 31 March 2021, the Statement of Cash Flows, Statement of Changes in Equity for the year ended 31 March 2021 and accounting policies and other explanatory information (together hereinafter referred to as 'Ind AS Financial Statements' or 'financial statements').

These financial statements are approved by the Board of Directors on 26.06.2021.

##### b) Basis of Preparation of financial statements

The separate financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) under historical cost convention on accrual basis as per the provisions of Companies Act 2013.

- Financial instruments – measured at fair value;
- Assets held for sale – measure at fair value less cost of sale;
- Plan assets under defined benefit plans – measure at fair value
- Employees share-based payments – measure at fair value

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

- Biological assets—measure fair value
- In addition, the carrying values of recognized assets and liabilities, designated as hedged items in fair value hedges that would otherwise be carried at cost, are adjusted to record changes in the fair values attributable to the risks that are being hedged in effective hedge relationship.

### **Current and Non-Current Classification:**

The Company presents assets and liabilities in the balance sheet based on current / non-current classification. An asset is classified as current when it satisfies any of the following criteria: it is expected to be realized in, or is intended for sale or consumption in, the Company's normal operating cycle. It is held primarily for the purpose of being traded;

- It is expected to be realized within 12 months after the reporting date; or
- It is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.
- All other assets are classified as non-current.
- A liability is classified as current when it satisfies any of the following criteria:
  - It is expected to be settled in the Company's normal operating cycle;
  - It is held primarily for the purpose of being traded
  - It is due to be settled within 12 months after the reporting date; or the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification
- All other liabilities are classified as non-current

### **c) Use of estimates and judgment**

The preparation of the financial statements in conformity with Ind AS, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

## ARUNJYOTI BIO VENTURES LIMITED

This note provides an overview of the areas where there is a higher degree of judgment or complexity. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation.

The areas involving critical estimates or judgments are:

S.No	Name of the estimate	Note No	Remarks
1	Fair value of unlisted equity securities	Not applicable	No unlisted equity shares are held by the company during the current financial year
2	Goodwill impairment	Not applicable	No amount provided during the current Financial year
3	Useful life of intangible asset	Not Applicable	No intangible assets held by the company for the current financial year
4	Measurement of contingent liabilities and contingent purchase consideration in a business combination	Not applicable	Contingent transactions are recognized based on happening contingent event. No contingent liabilities for the report
5	Current tax expense and current tax payable	Note No.7	As per the Ind AS.12
6	Deferred tax assets for carried forward tax losses	Note No.7	As per the Ind AS.12
7	Impairment of financial assets	Note No.1.3	As per Ind AS 16

**d. Standards issued but not effective (based on Exposure drafts available as on date)**

The amendments are proposed to be effective for reporting periods beginning on or after 1 April 2021.

**i). Issue of Ind AS 117 – Insurance Contracts:**

Ind AS 117 supersedes Ind AS 104 Insurance contracts. It establishes the principles for the recognition, measurement, presentation and

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

disclosure of insurance contracts within the scope of the standard. Under the Ind AS 117 model, insurance contract liabilities will be calculated as the present value of future insurance cash flows with a provision for risk.

Application of this standard is not expected to have any significant impact on the Company's financial statements.

### Amendments to existing Standards

Ministry of Corporate Affairs has carried out amendments of the following accounting standards:

1. Ind AS 103 – BusinessCombination - nil
2. Ind AS 1, Presentation of Financial Statements and Ind AS 8, Accounting Policies, Changes in Accounting Estimates and Errors
3. Ind AS 40 – InvestmentProperty - nil

The Company is in the process of evaluating the impact of the new amendments issued but not yet effective.

- e. Estimation of uncertainties relating to the global health pandemic from COVID-19 (COVID-19):

In assessing the recoverability of assets including trade receivables, unbilled receivables and investments, the Company has considered internal and external information up to the date of approval of these standalone financial statements including credit reports and economic forecasts. The Company has performed sensitivityanalysis on the assumptions used and based on current indicators of future economic conditions, the Company expects to recover the carrying amount of these assets. The eventual outcome of impact of the global health pandemic COVID-19 may be different from those estimated as on the date of approval of these standalone financial statements.

### 2. Significant accountingpolicies:

A summary of the significant accounting policies applied in the preparation of the financial statements is as given below. These accounting policies have been applied consistently to all the periods presented in the financial statements.

- 2.1 Ind AS 105: Non-Current Assets held for Sale or Discontinued Operations:

## ARUNJYOTI BIO VENTURES LIMITED

This standard specifies accounting for assets held for sale, and the presentation and disclosure for discontinued operations:

- (a) Assets that meet the criteria to be classified as held for sale to be measured at the lower of carrying amount and fair value less cost to sell, and depreciation on such assets to cease; and
- (b) Assets that meet the criteria to be classified as held for sale to be presented separately in the balance sheet and the results of discontinued operations to be presented separately in the statement of profit and loss.

S. No	Particulars of Disclosures	As at 31 <sup>st</sup> March 2021 (Rs.)	As at 31 <sup>st</sup> March 2020 (Rs.)
1	A Description of Non-Current Asset (Disposal group)	-	-
2	a description of the facts and circumstances of the sale, or leading to the expected disposal, and the expected manner and timing of that disposal	-	-
3	the gain or loss recognized in accordance with paragraphs 20–22 and, if not separately presented in the statement of profit and loss, the caption in the statement of profit and loss that includes that gain or loss	-	-

### 2.2 Ind AS 106: Exploration for Evolution of Mineral resources:

This standard specifies the financial reporting for the exploration for evaluation of mineral resources. In particular, this standard requires:

- a. Limited improvements to existing accounting practices for exploration and evaluation of expenditures
- b. Entities that recognize exploration and evaluation of assets to assess such assets for impairment in accordance with this standard and measure any impairment.

Disclosures that identify and explain the amounts in the entity's financial statements arising from the exploration for the evaluation of mineral resources and help users of those financial statements understand the

---

## ARUNJYOTI BIO VENTURES LIMITED

---

amount, timing and certainty of future cash flows from any exploration and evaluation of assets recognized.

This Ind AS 106 not applicable, the company is in the business of Infrastructure. Hence this Ind AS does not have any financial impact on the financial statements of the company.

### 2.3 Ind AS-16: Property, Plant and Equipment:

Property, Plant and Equipment are stated at cost less accumulated depreciation.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Property, plant and equipment which are significant to the total cost of that item of Property Plant and Equipment and having different useful life are accounted for as separately.

Gains or losses arising from derecognition of property, plant and equipment are measured as the difference between the net disposal proceeds and carrying amount of the asset is recognized in the statement of profit or loss when the asset is derecognized.

Depreciation on Property Plant and Equipment is provided on Straight line method. Depreciation is provided based on useful life as prescribed under part C of the schedule II of the Companies act, 2013.

S.No	Asset	Useful life (in Years)
1	Plant and Machinery	3-60
2	Electrical Installations	2-40
3	Lab Equipment	3-60
4	Computers	3-10
5	Office Equipment	2-20
6	Furniture & Fixtures	3-15
7	Vehicles	5-20

---

## ARUNJYOTI BIO VENTURES LIMITED

---

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (upto) the date on which asset is ready for use (disposed of).

### **Impairment**

Property Plant and Equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

### **2.4 Impairment Assets (Ind AS 36)**

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognised in the statement of profit and loss. Impairment loss recognised in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

The books of accounts of the company doesn't carry any impairment of assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### 2.5 Intangible assets (Ind AS 38):

Intangible assets are amortized over the estimated useful lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method are reviewed at least at each financial year end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as change in accounting estimates. The amortization expense on intangible assets with finite useful lives is recognized in profit or loss.

The books of accounts of the company doesn't carry any Intangible assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company

### 2.6 Cash Flow Statement (Ind AS 7):

Cash flows are reported using the indirect method under Ind AS 7, whereby profit/(loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

#### a). Non-cash items: Nil

#### b). Changes in Liability Arising from Financing Activity

Particulars	01-Apr-20	Cash Flow	31-Mar-21
		(Net)	
Current Borrowings	-	-	-
Non-current Borrowings	-	-	-
<b>Total</b>	-	-	-

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### **2.7 Operating Cycle:**

The Company has adopted its normal operating cycle as twelve months based on the nature of products and the time between the acquisition of assets for processing and their realization, for the purpose of current / non-current classification of assets and liabilities.

### **2.8 Capital Work in Progress**

The Books of Accounts of Company doesn't carry Capital work-in-progress during the reporting period.

### **2.9 Investments:**

Investments are classified as Non-Current and Current investments.

Investments, which are readily realisable and are intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.

Current investments are carried at lower of cost and fair value. Non-Current Investments are carried at cost less provision for other than temporary diminution, if any, in value of such investments.

The Books of Accounts of Company doesn't carry any Investments during the reporting period.

### **2.10 Effects of changes in foreign Rates (Ind AS 21):**

Foreign currency transactions are recorded at the exchange rates prevailing on the dates when the relevant transactions took place. Exchange difference arising on settled foreign currency transactions during the year and translation of assets and liabilities at the yearend are recognized in the statement of profit and loss.

In respect of Forward contracts entered into to hedge risks associated with foreign currency fluctuation on its assets and liabilities, the premium or discount at the inception of the contract is amortized as income or expense over the period of contract. Any profit or loss arising on the cancellation or renewal of forward contracts is recognized as income or expense in the period in which such cancellation or renewal is made.

The company has not entered any foreign exchange transactions during the reporting period; hence this accounting standard does not have financial impact on the financial statements.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### 2.11 Borrowing Costs (Ind AS 23):

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for the intended use or sale.

Investment income earned on temporary investment of specific borrowings pending their expenditure on qualifying assets is recognised in statement of profit and loss.

Discounts or premiums and expenses on the issue of debt securities are amortized over the term of related securities are included within borrowing costs. Premiums payable on early redemptions of debt securities, in lieu of future costs, are recognised as borrowing costs.

All other borrowing costs are recognised as expenses in the period in which it is incurred.

### 2.12 Revenue Recognition (Ind AS 18-Revenues):

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognized:

- a) Sales Revenue is recognized on dispatch to customers as per the terms of the order. Gross sales are net of returns and applicable trade discounts and excluding GST billed to the customers.
- b) Subsidy from Government is recognized when such subsidy has been earned by the company and it is reasonably certain that the ultimate collection will be made.
- c) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income" in the statement of profit and loss.
- d) All other incomes are recognized based on the communications held with the parties and based on the certainty of the incomes.

### 2.13 Accounting for Government Grants and Disclosure of Government Assistance (Ind AS 20):

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### **Government grants:**

Government grants are not recognised until there is reasonable assurance that the Company will comply with the conditions attached to them and that the grants will be received.

Government grants are recognised in the Statement of Profit and Loss on a systematic basis over the years in which the Company recognizes as expenses the related costs for which the grants are intended to compensate or when performance obligations are met.

Government grants, whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets and nonmonetary grants are recognised and disclosed as 'deferred income' under non-current liability in the Balance Sheet and transferred to the Statement of Profit and Loss on a systematic and rational basis over the useful lives of the related assets.

The benefit of a government loan at a below-market rate of interest and effect of this favorable interest is treated as a government grant. The loan or assistance is initially recognised at fair value and the government grant is measured as the difference between proceeds received and the fair value of the loan based on prevailing market interest rates and recognised to the income statement immediately on fulfillment of the performance obligations. The loan is subsequently measured as per the accounting policy applicable to financial liabilities.

The company has not received any Government Grants during the reporting period, hence this accounting standard does not have financial impact on the financial statements.

### **2.14 Inventories (Ind AS 2):**

Inventories at the year-end are valued as under:

Raw Materials, Packing Material, Components, Consumables and Stores & Spares	At Cost as per First in First Out Method (FIFO)
--	---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

- Cost of Material excludes duties and taxes which are subsequently recoverable.
- Stocks at Depots are inclusive of duty, wherever applicable, paid at the time of dispatch from Factories.
- Based on the information provided the difference between physical verification and valuation of the of inventories are charged to the profit and loss account.

### **2.15 Trade Receivables – Doubtful debts:**

Provision is made in the Accounts for Debts/Advances which is in the opinion of Management Are Considered doubtful of Recovery.

### **2.16 Retirement and other Employee Benefits:**

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

Gratuity liability is a defined benefit obligation and the cost of providing the benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for this plan using the projected unit credit method. Actuarial gains and losses for defined benefits plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### **2.17 Ind AS 17- Leases**

A Lease is classified as a Finance Lease if it transfers substantially all the risks and rewards incidental to ownership. A lease is classified as an operating lease if it does not transfer substantially all the risks and rewards incidental to ownership.

Finance charges in respect of finance lease obligations are recognized as finance costs in the statement of profit and loss. In respect of operating leases for premises, which are cancellable / renewable by mutual consent on agreed terms, the aggregate lease rents payable are charged as rent in the Statement of Profit and Loss.

### **2.18 Insurance Claims:**

Insurance Claims are accounted for on the basis of claims admitted/excepted to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

### **2.19 Earnings per Share (Ind AS 33):**

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

### **2.20 Provisions, Contingent Liabilities and Contingent Assets (Ind AS 37):**

The Company recognized provisions when there is present obligation as a result of past event and it is probable that there will be an outflow of resources required to settle the obligation in respect of which a reliable estimate can be made. A disclosure for Contingent liabilities is made

## ARUNJYOTI BIO VENTURES LIMITED

when there is a possible obligation or present obligations that may, but probably will not, require an outflow of resources. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates. Contingent assets are neither recognized nor disclosed in the financial statements.

### Contingent Liabilities not provided for and commitments(In Rupees)

Nature of Contingent Liability	March 31, 2021	March 31, 2020
i. Unexpired guarantees issued on behalf of the company by Banks for which the Company has provided counter guarantee	Nil	Nil
ii. Bills discounted with banks which have not matured	Nil	Nil
iii. Corporate Guarantees issued by Company on behalf of others to Commercial Banks & Financial Institutions	Nil	Nil
iv. Collateral Securities offered to Banks for the limit Sanctioned to others	Nil	Nil
v. Legal Undertakings given to Customs Authorities for clearing the imports	Nil	Nil
vi. Claims against the company not acknowledged as debts		
a. Excise	Nil	Nil
b. Sales Tax	Nil	Nil
c. Service Tax	Nil	Nil
d. Income Tax	Nil	Nil
e. Civil Proceedings	Nil	Nil
f. Company Law Matters	Unascertainable	Unascertainable
g. Criminal Proceedings	Unascertainable	Unascertainable
h. Others	Nil	Nil
vii. Estimated amounts of contracts remaining to be executed on Capital Account and not provided for	Nil	Nil

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### **2.21 Prior Period and Extraordinary and Exceptional Items:**

- (i) All Identifiable items of Income and Expenditure pertaining to prior period are accounted through "Prior Period Items".
- (ii) Extraordinary items are income or expenses that arise from events or transactions that are clearly distinct from the ordinary activities of the enterprise and, therefore, are not expected to recur frequently or regularly. The nature and the amount of each extraordinary item be separately disclosed in the statement of profit and loss in a manner that its impact on current profit or loss can be perceived.
- (iii) Exceptional items are generally non-recurring items of income and expenses within profit or loss from ordinary activities, which are of such, nature or incidence.

### **2.22 Financial Instruments (Ind AS 107 Financial Instruments: (Disclosures))**

#### **I. Financial assets:**

##### **A. Initial recognition and measurement**

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

##### **a) Financial assets carried at amortized cost (AC)**

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

##### **b) Financial assets at fair value through profit or loss (FVTPL)**

A Financial asset which is not classified as AC or FVOCI are measured at FVTPL e.g. investments in mutual funds. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss is recognised in profit or loss and presented net in the Statement of Profit and Loss within other gains/(losses) in the period in which it arises.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

**c) Financial assets at fair value through other comprehensive income (FVTOCI)**

A financial asset is measured at FVTOCI if it is held within a business model whose Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

**B. Investments in subsidiaries**

The Company has accounted for its investments in subsidiaries at cost and not adjusted to fair value at the end of each reporting period. Cost represents amount paid for acquisition of the said investments.

## **II. Financial Liabilities**

**A. Initial recognition**

All financial liabilities are recognized at fair value.

**B. Subsequent measurement**

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

## **2.23 Operating Segments (Ind AS 108)**

Operating segment is a component of an entity:

- a. That engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity).
- b. Whose operating results are regularly reviewed by the entity's chief operating decision maker to make decision about resources to be allocated to the segments and assess its performance, and
- c. For which discrete financial information is available.

The company is in the business Infrastructure. Hence IND AS 108 is not applicable.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### 2.24 Events After the Reporting Period (Ind AS-10)

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting period and the date on which financial statements are approved by the Board of Directors in case of accompany, and, by the corresponding approving authority in case of any other entity for issue. Two types of events can be identified:

- a. Those that provide evidence of conditions that existed at the end of the reporting period (adjusting events after the reporting period) and
- b. Those that are indicative of conditions that arose after the reporting period (non-adjusting events after the reporting period).

An entity shall adjust the amounts recognized in its financial statements to reflect adjusting events after the reporting period.

### 2.25 Construction Contracts (Ind AS -11):

Construction contract is a contract specifically negotiated for the construction of an asset or a combination of assets that are closely interrelated or interdependent in terms of their design, technology, and function or their ultimate purpose or use.

The company does not have any construction contracts for the year ended.

### 2.26 Income Taxes (Ind AS 12)

Tax Expense for the period comprises of current and deferred tax.

- **Current Tax:**

Current Tax on Income is determined and provided on the basis of taxable income computed in accordance with the provisions of the Income Tax Act, 1961.

In the year in which 'Minimum Alternative Tax '(MAT) on book profits is applicable and paid, eligible MAT credit equal to the excess of MAT paid over and above the normally computed tax, is recognized as an asset to be carried forward for set off against regular tax liability when it is probable that future economic benefit will flow to the Company within the MAT credit Entitlement period as specified under the provisions of Income Tax Act, 1961.

---

## ARUNJYOTI BIO VENTURES LIMITED

---

- **Deferred Taxes:**

Deferred tax liabilities are recognized for all timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

At each reporting date, the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

### **2.27 Retirement and other Employee Benefits:**

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

Gratuity liability is a defined benefit obligation and the cost of providing the benefits under this plan is determined on the basis of actuarial valuation at each year-end. Actuarial valuation is carried out for this plan using the projected unit credit method. Actuarial gains and losses for defined benefits plan is recognized in full in the period in which they occur in the statement of profit and loss.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the year-end. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The Company presents the leave as a current liability in the balance sheet, to the extent it does not have an unconditional right to defer its settlement for 12 months after the reporting date.

### **New and Amended Standards**

#### **2.28 Amendment to Ind AS 116: COVID -19 Related Rent Concessions:**

The amendments provide relief to lessees from applying Ind AS 116 guidance on lease modification accounting for rent concessions arising as a direct consequence of Covid-19 pandemic. As a practical expedient, a lessee may elect not to assess whether a Covid-19 related rent concession from a lessor is lease modification. A lessee that makes this election accounts for any change in lease payments resulting from COVID-19 related rent concession the same way it would account for the changes under Ind AS 116, if changes were not lease modifications. This Amendment had no impact on the standalone financial statements of the Company.

#### **2.29 Amendment to Ind AS 1 and Ind AS 8: Definition of material:**

The Amendments provide a new definition of material that states “information is material if omitting, misstating or obscuring it is reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements, which provide financial information about specific reporting entity”. The amendments clarify that materiality will depend on the nature of magnitude of information, either individually or in combination with other information, in the context of the financial year statements. A misstatement of information is material if it could reasonably be expected to influence decisions made by the primary users. These amendments had no impact on standalone financial statements of the company.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

### **2.30 Amendment to Ind AS 107 and Ind AS 109: Interest Rate Benchmark Reform:**

The amendments to Ind AS 109 Financial Instruments: Recognition and Measurements provide number of reliefs, which apply to all hedging relationships that are directly affected interest rate benchmark reform. A hedging relationship is affected if the reform gives rise to uncertainty about the timing and/or amount of benchmark-based cash flow of hedging items or hedging instrument. These amendments have no impact on the standalone financial statements of the company as it does not have any interest rate hedge relation.

The amendment to Ind AS 107 prescribe the disclosure which entities are required to make for hedging relationship to which the reliefs as per the amendments in Ind AS 109 are apply. This amendment had no impact on the standalone financial statement of the company.

## ARUNJYOTI BIO VENTURES LIMITED

**Note 1: Property, Plant Equipment** Amount Rs.

Particular	Land	Buildings	Plant & Machinery	Electrical Installations	Lab Equipments	Computers	Office Equipment	Furniture & Fixtures	Vehicles	Total
<b>Cost/Deemed Cost:</b>										
at 1st April 2019	-	-	-	-	-	-	-	-	-	-
Additions	-	-	-	-	-	-	-	-	-	-
Deletions	-	-	-	-	-	-	-	-	-	-
<b>As at March 2020</b>	-	-	-	-	-	-	-	-	-	-
Additions	-	-	-	-	-	-	-	-	-	-
Deletions	-	-	-	-	-	-	-	-	-	-
<b>As at March 2021</b>	-	-	-	-	-	-	-	-	-	-
<b>Depreciation/Impairment</b>										
at 1st April 2019	-	-	-	-	-	-	-	-	-	-
Depreciation for the year	-	-	-	-	-	-	-	-	-	-
Disposals	-	-	-	-	-	-	-	-	-	-
Impairment	-	-	-	-	-	-	-	-	-	-
<b>As at March 2020</b>	-	-	-	-	-	-	-	-	-	-
Depreciation for the year	-	-	-	-	-	-	-	-	-	-
Disposals	-	-	-	-	-	-	-	-	-	-
Impairment	-	-	-	-	-	-	-	-	-	-
<b>As at March 2021</b>	-	-	-	-	-	-	-	-	-	-
<b>Net Book Value</b>										
As at March 2021	-	-	-	-	-	-	-	-	-	-
As at March 2020	-	-	-	-	-	-	-	-	-	-

Note 1(e): Other Intangible Assets				
Particular	Computer Software	Patentents	Trade marks	Total
<b>Cost/Deemed Cost:</b>				
at 1st April 2019	-	-	-	-
Additions	-	-	-	-
Deletions	-	-	-	-
<b>As at March 2020</b>	-	-	-	-
Additions	-	-	-	-
Deletions	-	-	-	-
<b>As at March 2021</b>	-	-	-	-
<b>Depreciation/Impairment</b>				
at 1st April 2019	-	-	-	-
Depreciation for the year	-	-	-	-
Disposals	-	-	-	-
<b>As at March 2020</b>	-	-	-	-
Depreciation for the year	-	-	-	-
Disposals	-	-	-	-
Impairment	-	-	-	-
<b>As at March 2021</b>	-	-	-	-
<b>Net Book Value</b>				
As at March 2021	-	-	-	-
As at March 2020	-	-	-	-

## ARUNJYOTI BIO VENTURES LIMITED

Notes annexed to and forming part of the Financial Statements

Note. 4: Investments

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non Current</b>			
1	Investments in quoted shares	-	-	-
2	investment in unquoted shares of subsidiaries	-	-	-
3	investment in Joint Ventures	-	-	-
4	investment in Preference Shares	-	-	-
5	Investment in partnerships	-	-	-
	<b>Total</b>	-	-	-
	<b>Current</b>			
1	Investments in quoted shares	-	-	-
2	investment in unquoted shares of subsidiaries	-	-	-
3	investment in Joint Ventures	-	-	-
4	investment in Preference Shares	-	-	-
5	Investment in partnerships	-	-	-
	<b>Total</b>	-	-	-

Note 5: Trade Receivables

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non Current</b>			
A	<b>Secured and considered good:</b>			
	-From Related party	-	-	-
	-From Others	-	-	-
B	<b>Unsecured and considered good:</b>			
	-From Related party	-	-	-
	-From Others	-	-	-
C	<b>Doubtful:</b>			
	-From Related party	-	-	-
	-From Others	-	-	-
	Less: allowance for doubtful debts	-	-	-
	<b>Total</b>	-	-	-
	<b>Current:</b>			
A	<b>Secured and considered good:</b>			
	-From Related party	-	-	-
	-From Others	-	-	-
B	<b>Unsecured and considered good:</b>			
	-From Related party	-	-	-
	-From Others	1,83,81,369	2,67,25,481	2,35,59,851
C	<b>Doubtful:</b>			
	-From Related party	-	-	-
	-From Others	-	-	-
	Less: allowance for doubtful debts	-	-	-
	<b>Total</b>	<b>1,83,81,369</b>	<b>2,67,25,481</b>	<b>2,35,59,851</b>

## ARUNJYOTI BIO VENTURES LIMITED

### Note 6: Loans

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non Current:</b>			
A	Loans :			
1	To related parties	-	-	-
2	to other body corporate	-	-	-
3	to employees	-	-	-
4	Security Deposits:	1,49,71,191.68	1,49,71,192.00	1,49,71,192.00
5	Less: allowances for Doubtful loans	-	-	-
	<b>Total Loans</b>	<b>1,49,71,191.68</b>	<b>1,49,71,192.00</b>	<b>1,49,71,192.00</b>
	<b>Notes:</b>			
1	Considered fgood	-	-	-
2	Considered Doubt full, Provided:	-	-	-
3	To related parties	-	-	-
4	to other body corporate	-	-	-
5	to employees	-	-	-
	<b>Total</b>	<b>1,49,71,191.68</b>	<b>1,49,71,192.00</b>	<b>1,49,71,192.00</b>
	<b>Current:</b>			
A	Loans :			
1	To related parties	-	-	-
2	to other body corporate	-	-	-
3	to employees	-	-	-
4	Security Deposits:	-	-	-
5	Less: allowances for Doubtful loans	-	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Notes:</b>			
1	Considered fgood	-	-	-
2	Considered Doubt full, Provided:	-	-	-
3	To related parties	-	-	-
4	to other body corporate	-	-	-
5	to employees	-	-	-

### Note 7: Income Taxes

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	(Amt. in Rs.) As at March 31, 2019
	<b>a). Current Tax liability</b>			
	Opening Balance			
	Add: Current tax payable for the year	-	-	-
	Less: Taxes Paid	-	-	-
	<b>Closing balances</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>b). Current Tax Asset</b>			
	Opening Balance	-	-	-
	Add: Taxes paid/TDS Receivable	-	-	-
	Less: Current tax payable for the year	-	-	-
	<b>Closing Balance</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>c). Differed Tax Asset</b>			
	Differed tax Asset - (A)	-	-	-
	Provision for Employees	-	-	-
	Waranty Provisions	-	-	-
	Loss allowance on financial and Contract Assets	-	-	-
	Others	-	-	-
	<b>Sub Total (A)</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Differed tax Liability- (B)</b>			
	on Written down value of fixed assets	-	-	-
	Others	-	-	-
	<b>Sub Total (B)</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Total (A-B)</b>	<b>-</b>	<b>-</b>	<b>-</b>

## ARUNJYOTI BIO VENTURES LIMITED

**Note 8: Other Non Current Assets**

(Amt. in Rs.)

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
<b>A</b>	<b>Other Non-Current Assets</b>			
	Capital Advances	-	-	-
	Advances other than capital advances	-	-	-
	<b>Security Deposits:</b>	-	-	-
	Government Authorities - Electricity Dept	-	-	-
	— Advances to Related Parties	-	-	-
	— Other Advances	-	-	-
	<b>Others - unsecured</b>	-	-	-
	<b>Total of Other Non-current Assets</b>	-	-	-

**Note 9: Inventories**

(Amt. in Rs.)

	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
1	Raw Material	-	-	-
2	Packing Material	-	-	-
3	Work In Process	-	-	-
4	Finished Goods	2,59,478	2,96,484	52,89,553
5	Consumables & Stores and Spares	-	-	-
6	Property under Development	-	-	-
	<b>Total Inventories</b>	<b>2 59 478</b>	<b>2 96 484</b>	<b>52 89 553</b>

**Notes 9.1: Disclosure of Inventories pledged as security for liabilities as follows**

S.No	Particulars	Carrying Amount	Security Pledged Against	Security Pledged Against
<b>A</b>	<b>As at 31st March 2020</b>			
a	Raw Material			
b	Work In Process			
c	Finished Goods			
<b>B</b>	<b>As at 31st March 2019</b>			
a	Raw Material			
b	Work In Process			
c	Finished Goods			
	<b>Total Inventories</b>	-	-	-

**Note 10: Cash and Cash Equivalents**

(Amt. in Rs.)

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
1	Cash and Cash Equivalents (Note 10.1)	852	7,511	2,296
2	Bank Balances other than Cash and Cash Equivalents	80,86,193	1,11,68,888	34,55,929
	<b>Total Cash and Cash Equivalents</b>	<b>80 87 045</b>	<b>1 11 76 399</b>	<b>34 58 225</b>

**Notes:**

1. In the Balance sheet Cash comprises cash and demand deposits.
2. Cash equivalents are held for the purpose of short term cash commitments rather than for investment or other purpose

**Note 10.1: Cash and Cash Equivalents**

(Amt. in Rs.)

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Bank and Cash Balances</b>			
	<b>On Current Accounts:</b>			
1	SBI	-	-	-
2	Cheques/drafts on hand	-	-	-
3	Cash on hand	852	7,511	2,296
	<b>Total Cash and Cash Equivalents</b>	<b>852</b>	<b>7 511</b>	<b>2 296</b>

## ARUNJYOTI BIO VENTURES LIMITED

### Note 11: Other Current Assets

(Amt in Rs.)

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Other Current Assets</b>			
1	<b>Capital Advances:</b>			
	Advances to Plant and Machinery	-	-	-
2	<b>Advances other than capital advances:</b>			
	MAT Credit Entitlement	-	45,710	84,319
3	Security Deposits	-	-	-
4	Advances to Related Parties	-	-	-
5	<b>Other Advances:</b>			
	GST Input	46,23,707	56,23,328	72,83,938
	Interest Receivable	-	-	-
	Advances to Employees	65,481	1,55,481	1,91,401
	Others	6,44,793	-	-
	<b>Total of Other current Assets</b>	<b>53,33,981</b>	<b>58,24,519</b>	<b>75,59,658</b>

### Note 11.1: Non Current Assets Classified as Held for Sale

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non-Curret Assets</b>			
1	Plant, Property and Equipment	-	-	-
2	Others	-	-	-
	<b>Total Non Current Assets Classified as Held for Sale</b>	<b>-</b>	<b>-</b>	<b>-</b>

### Note 12: Equity share capital

#### a. Equity share capital

(Amt. in Rs.)

	As at Mar 31, 2021		As at Mar 31, 2020		As at March 31, 2019	
	No. of Shares	Amount in Rs.	No. of Shares	Amount in Rs.	No. of Shares	Amount in Rs.
<b>Authorised</b>						
Equity shares of Rs. 10 each	35,00,000	3,50,00,000	35,00,000	3,50,00,000	35,00,000	3,50,00,000
<b>Issued</b>						
Equity shares of Rs. 10 each	20,70,900	2,07,09,000	20,70,900	2,07,09,000	20,70,900	2,07,09,000
<b>Subscribed and Paid-up</b>						
Equity shares of Rs. 10 each fully paid-up	20,70,900	2,07,09,000	20,70,900	2,07,09,000	20,70,900	2,07,09,000
<b>Total</b>	<b>20,70,900</b>	<b>2,07,09,000</b>	<b>20,70,900</b>	<b>2,07,09,000</b>	<b>20,70,900</b>	<b>2,07,09,000</b>

\*2070900 shares of Rs. 10 each allotted as fully paid up pursuant to contract without payment being received in cash.

#### b. Reconciliation of the number of equity shares outstanding and the amount of share capital

	As at Mar 31, 2021		As at Mar 31, 2020		As at March 31, 2019	
	No. of Shares	Amount	No. of Shares	Amount	No. of Shares	Amount
<b>Equity Shares</b>						
<b>Issued and Subscribed:</b>						
Shares outstanding at the beginning of the year	20,70,900	2,07,09,000	20,70,900	2,07,09,000	20,70,900	2,07,09,000
Add: Issued During the year for cash	-	-	-	-	-	-
Add: Shares issued at ESOP trust	-	-	-	-	-	-
Shares outstanding at the end of the year	<b>20,70,900</b>	<b>2,07,09,000</b>	<b>20,70,900</b>	<b>2,07,09,000</b>	<b>20,70,900</b>	<b>2,07,09,000</b>

#### c. Terms / rights attached to equity Shares

The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholdings.

#### d. Shares reserved for issue underwriter options

Nil

#### e. Detail of Rights Issues

Nil

#### f. details of shares held by Holding/Ultimate Holding Company

Nil

#### g. Details of shares issued for consideration other than cash

Nil

#### h. Shares in the company held by each shareholder holding more than 5 percent

Name of the Shareholder	As at Mar 31, 2021		As at Mar 31, 2020		As at March 31, 2019	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding	No. of Shares held	% of Holding
P SRINIVASA RAO	1,25,815	6.08%	1,25,815	6.08%	1,25,815	6.08%
P LEELA MADHURI DEVI	1,45,984	7.05%	1,45,984	7.05%	1,32,802	6.41%
RAGHU RAM RENDUCHINTALA	2,05,954	9.95%	2,05,954	9.95%	2,05,954	9.95%
PRAVEEN KUMAR PABBATHI	1,04,076	5.03%	1,04,076	5.03%	1,04,076	5.03%

\*Includes 10 Equity shares of Rs. 10 each fully paid up held by nominee.

## ARUNJYOTI BIO VENTURES LIMITED

i. Dividend Declaration Details		Amount in Rs.		
Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019	
Cash Dividend Declared for the Year 31 march 2019		-	-	
Dividend Distribution Tax on final Dividend		-	-	
Interim Dividend for the year ended on 31 March 2020				
<b>Total</b>		-	-	
Proposed Dividend on Equity Shares				
Final Dividend for the year ended 31 March 2020				
Distribution Tax on Proposed Dividend				
<b>Total</b>		-	-	

### Note 12.1 Other equity

	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
<b>Capital Reserve:</b>			
Balance at the beginning of the year	23,33,750	23,33,750	23,33,750
Add: Addition During the Year	-	-	-
<b>Balance at the end of the year</b>	<b>23,33,750</b>	<b>23,33,750</b>	<b>23,33,750</b>
<b>Securities Premium:</b>			
Balance at the beginning of the year	-	-	-
Add: Securities Premium on shares issued during the year	-	-	-
<b>Balance at the end of the year</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Retained earnings</b>			
Balance at the beginning of the year	(42,76,778)	(53,33,955)	(57,72,203)
Add: Addition During the Year	6,82,613	10,57,177	3,88,248
Less: Transfers	24,626	-	-
<b>Balance at the end of the year</b>	<b>(36,18,791)</b>	<b>(42,76,778)</b>	<b>(53,83,955)</b>
<b>Total other Equity</b>	<b>(12,85,041)</b>	<b>(19,43,028)</b>	<b>(30,50,205)</b>

### Note 11.2 Other Reserves

	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
<b>Debentures Redemption Reserves:</b>			
Balance at the beginning of the year		-	-
Add: Addition during the Year		-	-
<b>Balance at the end of the year</b>		<b>-</b>	<b>-</b>
<b>Capital Redemption Reserves:</b>			
Balance at the beginning of the year		-	-
Add: Addition during the Year		-	-
<b>Balance at the end of the year</b>		<b>-</b>	<b>-</b>
<b>Investment Fluctuation Reserves:</b>			
Balance at the beginning of the year		-	-
Add: Addition during the Year		-	-
<b>Balance at the end of the year</b>		<b>-</b>	<b>-</b>
<b>Total Other Reserves</b>		<b>-</b>	<b>-</b>

## ARUNJYOTI BIO VENTURES LIMITED

### Note 13: Borrowings

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b><u>Non-Current:</u></b>			
1	Bonds	-	-	-
2	Debentures(Secured)	-	-	-
3	<b>Term loans:</b>	-	-	-
i	Secured	-	-	-
	From Bank			
	Loan From Vijaya lakshmi Vilas Bank Ltd (The loan account became NPA and company defaulted in making payment)	-	-	-
	Loan From Indian Overseas Bank (The loan account became NPA and company defaulted in making payment)	-	-	-
ii	Unsecured	-	-	-
iii	From banks	-	-	-
iv	Working Capital	-	-	-
v	Deferred payment liabilities	-	-	-
vi	Other Loans	-	-	-
vii	-Finance lease obligations	-	-	-
viii	- Preference shares	-	-	-
ix	Interest-free sales Tax deferral loan from state Govt.	-	-	-
4	<b>Unsecured Loans</b>			
i	Loans from Individuals other than Banks	-	-	-
ii	Loans from Related Companies	-	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b><u>Current:</u></b>			
1	Bonds	-	-	-
2	Debentures(Secured)	-	-	-
3	<b>Term loans:</b>	-	-	-
i	Secured	-	-	-
ii	Unsecured	-	-	-
iii	From banks	-	-	-
iv	Working Capital	-	-	-
v	Deferred payment liabilities	-	-	-
vi	Other Loans	-	-	-
vii	-Finance lease obligations	-	-	-
viii	- Preference shares	-	-	-
ix	Interest-free sales Tax deferral loan from state Govt.	-	-	-
4	<b>Unsecured Loans</b>			
	Loans from Related parties	-	-	-
5	<b>Cash Credit</b>			
i	Lakshmi Vilas Bank-2881 (The Company defaulted in payment of loan interest and the CC account became NPA)	-	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>

## ARUNJYOTI BIO VENTURES LIMITED

### Note 14: Trade Payables

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non Current:</b>			
A	<b>Trade payables</b>			
	Dues to Micro, Small and Medium Enterprises	-	-	-
	Dues to other than Micro, Small and Medium Enterprises	-	-	-
	<b>Sub Total</b>	-	-	-
B	<b>Trade payables</b>			
	Dues to Micro, Small and Medium Enterprises	-	-	-
	Dues to other than Micro, Small and Medium Enterprises	-	-	-
	<b>Total</b>	-	-	-
	<b>Current:</b>			
A	<b>Trade payables</b>			
	Dues to Micro, Small and Medium Enterprises	-	-	-
	Dues to other than Micro, Small and Medium Enterprises	-	-	-
	<b>Sub Total</b>	-	-	-
B	<b>Trade payables</b>			
	Dues to Micro, Small and Medium Enterprises	-	-	-
	Dues to other than Micro, Small and Medium Enterprises	1,31,03,211	2,18,42,239	2,10,57,322
	<b>Total</b>	1,31,03,211	2,18,42,239	2,10,57,322

**Note:** Dues to micro and small enterprises - As per Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED' Act) This information has been determined to the extent such parties have been identified on the basis of information available with the Company.

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	Principal amount remaining unpaid to any supplier as at the end of the year.	-	-	-
	Amount of interest due remaining unpaid to any supplier as at the end of the year.	-	-	-
	Amount of interest paid under MSMED Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during the year.	-	-	-
	Amount of interest due and payable for the period of delay in making payment (where the principal has been paid but interest under the MSMED Act, 2006 not paid).	-	-	-
	Amount of interest accrued and remaining unpaid at the end of year.	-	-	-
	Amount of further interest remaining due and payable even in the succeeding year.	-	-	-

### Note 15: Other Financial Liabilities

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non Current:</b>			
1	Investor endowment protection fund			
4	<b>Others:</b>			
i	Retention money for capital projects	-	-	-
ii	Payable towards capital expenditure	-	-	-
iii	Payable towards Services received	-	-	-
iv	Payable towards other expenses	-	-	-
v	Interest accrued but no due on borrowings	-	-	-
	<b>Total</b>	-	-	-
	<b>Current</b>			
1	Current Maturities of Long Term Borrowings	-	-	-
2	Current Maturities of finance lease obligation	-	-	-
3	Investor endowment protection fund	-	-	-
4	<b>Others:</b>			
i	Retention money for capital projects	-	-	-
ii	Payable towards capital expenditure	-	-	-
iii	Payable towards Services received	-	-	-
iv	Payable towards other expenses	-	-	-
v	Interest accrued but no due on borrowings	-	-	-
	<b>Total</b>	-	-	-

## ARUNJYOTI BIO VENTURES LIMITED

### Note 16: Provisions

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	<b>Non Current:</b>			
	a). Provision for Employee Benefits			
	For Provident Fund	-	-	-
	For gratuity			
	Provision for compensated absences	-	-	-
	b). Others	-	-	-
	Service Warranties	-	-	-
	Statutory Dues	-	-	-
	Legal Claims	-	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Current:</b>			
	a). Provision for Employee Benefits			
	For Provident Fund	-	-	-
	For gratuity			
	Provision for compensated absences	-	-	-
	b). Others	-	-	-
	Service Warranties	-	-	-
	Statutory Dues	2,39,838	2,51,859	84,319
	Legal Claims	-	-	-
	<b>Total</b>	<b>2,39,838</b>	<b>2,51,859</b>	<b>84,319</b>

### Note 17: Other current Liabilities

S.No	Particulars	As at Mar 31, 2021	As at Mar 31, 2020	As at March 31, 2019
	a). Revenue Received in Advance			
	Advances From customers	-	-	-
	b). Other Payables			
	TDS Payable	10,436	65,063	1,40,427
	Income Tax Payable	-	-	-
	Service Tax Payable	-	-	-
	Listing fee, Custody Fee, Issuer Fee	-	-	-
	Provision for Employee Benefit Expenses	-	-	-
	Other Expenses Payable	1,41,28,310	1,79,68,940	1,58,47,616
	Audit fee payable	1,00,000	1,00,000	-
	<b>Total</b>	<b>1,42,38,746</b>	<b>1,81,34,003</b>	<b>1,59,88,043</b>

## ARUNJYOTI BIO VENTURES LIMITED

### Note 18: Revenue from operations

		(Amt. in Rs.)		
	Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
A	Revenue from contracts with customers disaggregated based on nature of product or services			
	Revenue from Sale of Products			
	a). Sale of Manufactured Goods	5,51,28,875	7,30,88,613	3,71,74,710
	b). Stock in Trade	-	-	-
	<b>Net Revenue</b>	<b>5,51,28,875</b>	<b>7,30,88,613</b>	<b>3,71,74,710</b>
	Revenue from Sale Service			
	a). Software services	-	-	-
	b). Other Services	-	-	-
	<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>
	Other Operating Revenues			
B	a). Export Incentives	-	-	-
	b). Royalty Received	-	-	-
	From subsidiaries and associates	-	-	-
	From others	-	-	-
	c). Scrap Sale	-	-	-
	d). Others	-	-	-
	<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>
	<b>Total Revenue from Operations</b>	<b>5,51,28,875</b>	<b>7,30,88,613</b>	<b>3,71,74,710</b>
	Disaggregated revenue information			
	Revenue from contracts with customers disaggregated based on geography			
	a). Domestic	-	-	-
	b). Export	-	-	-
	<b>Sub total</b>	<b>-</b>	<b>-</b>	<b>-</b>
	C) Reconciliation of Gross Revenue from Contracts With Customers			
	Gross Revenue	-	-	-
	Less: Discount	-	-	-
	Less: Returns	-	-	-
	Less: Price Concession	-	-	-
	Less: Incentives and performance bonus	-	-	-
	Less: Goods and Service Tax	-	-	-
	<b>Net Revenue recognised from Contracts with Customers</b>	<b>-</b>	<b>-</b>	<b>-</b>

C1 Terms conditions on performance warranty

C2 Credit period

C3 The Company does not have any remaining performance obligation as contracts entered for sale of goods are for a shorter duration. There are no contracts for sale of services wherein, performance obligation is unsatisfied to which transaction price has been allocated.

## ARUNJYOTI BIO VENTURES LIMITED

### Note 19: Other Income

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
<b>Interest income</b>			
a). Financial assets mandatorily measured at fair value through profit or loss	-	-	-
b). Interest income on financial assets fair valued through other comprehensive income	-	-	-
-Non Convertible debentures	-	-	-
c). Financial assets carried at amortised cost			
Tax free bonds and government bonds	-	-	-
Deposits with banks and others	-	-	-
<b>Sub total (i)</b>	-	-	-
<b>Dividend Income</b>			
a). Investments mandatorily measured at fair value through profit or loss	-	-	-
b). Equity investment designated at fair value through other comprehensive income	-	-	-
<b>Sub total (ii)</b>	-	-	-
Unwinding of discount on security deposits(iii)	-	-	-
Government grants (iv)	-	-	-
Foreign Exchange Loss/Gain (v)	15,376	-	-
Discount Received(vi)	2,887	25,745	15,627
<b>Total(i+ii+iii+iv+v+vi)</b>	<b>18,263</b>	<b>25,745</b>	<b>15,627</b>

### Note 20: Net gain/(Loss) on de-recognition of financial assets at amortised cost

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Profit on sale of land and buildings	-	-	-
Written off of liability	-	-	-
<b>Total Gain</b>	-	-	-

### Note 21: Net gain/(Loss) on reclassification of financial assets

Deposits with banks and others	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Profit on sale of land and buildings	-	-	-
Written off of liability	-	-	-
<b>Total Gain</b>	-	-	-

### Note 22: Cost of Material Consumed

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
<b>A. Raw Material Consumed</b>			
Raw materials at the beginning of the year	2,96,484	52,89,553	-
Add: Purchases During the year	4,66,35,013	5,59,03,935	3,67,13,180.0
Less: Raw materials at the end of the year	2,59,478	2,96,484	52,89,553.0
<b>Total cost of raw material consumed</b>	<b>4,66,72,019</b>	<b>6,08,97,004</b>	<b>3,14,23,627</b>
(Write down value of inventories Rs.0 and written down value of material due to obsolescence Rs.0 these amount included in the cost material consumed)			
<b>B). Packing Material</b>			
Packing materials at the beginning of the year	-	-	-
Add : Purchases During the year	-	-	-
Less: Packing materials at the end of the year	-	-	-
<b>Total cost of packing materials consumed (B)</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total cost of Materials consumed (B)</b>	<b>4,66,72,019</b>	<b>6,08,97,004</b>	<b>3,14,23,627</b>

## ARUNJYOTI BIO VENTURES LIMITED

**Note 23: Changes in inventories of finished goods, work-in-progress and stock-in-trade**

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Opening Balance	-	-	-
Finished Goods	-	-	-
Work in Progress	-	-	-
Stock in Trade (Including Goods in Transit)	-	-	-
Spares and Consumables	-	-	-
<b>Total Opening Balances</b>	<b>-</b>	<b>-</b>	<b>-</b>
Closing Balance	-	-	-
Finished Goods	-	-	-
Work in Progress	-	-	-
Stock in Trade (Including Goods in Transit)	-	-	-
Spares and Consumables	-	-	-
<b>Total Closing Balance</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total Changes in inventories of finished goods, work-in-progress and stock-in-trade</b>	<b>-</b>	<b>-</b>	<b>-</b>

**Note 24: Direct Expenses**

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Custom Duty	14,68,542	-	-
<b>Total</b>	<b>14,68,542</b>	<b>-</b>	<b>-</b>

**Note 25 Employee Benefits**

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Managerial Remuneration	6,00,000	12,59,000	12,32,500
Salaries, Wages, Bonus etc.	17,79,000	18,74,436	30,49,931
Contribution to P.F, E.S.I and Other Statutory Funds	-	-	-
Employee share based payment expenses	-	-	-
Gratuity	-	-	-
Leave compensation	-	-	-
Post-employment pension benefits	-	-	-
Post-employment medical benefits	-	-	-
Staff welfare expenses	-	1,070	17,702
<b>Total Employee benefits</b>	<b>23,79,000</b>	<b>31,34,506</b>	<b>43,00,133</b>

**Note 26: Finance Cost**

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
<b>Interest and finance charges on financial liabilities carried at amortised cost</b>			
a). Interest on Bank Borrowings	-	-	-
b). Interest on Bill Discounting	-	-	-
c). Other Interest Expenses (Bank Charges)	15,704	1,929	1,431
Less: Amount Capitalised	-	-	-
<b>Total Interest on financial liabilities carried at amortised cost</b>	<b>15,704</b>	<b>1,929</b>	<b>1,431</b>
Interest on Trade payables (as per MSME Act)	-	-	-
Interest on delayed payment of statutory dues	-	-	-
Unwinding of discount on provision	-	-	-
Exchange difference regarded as adjustment to borrowing costs	-	-	-
Dividend on redeemable preference shares (including dividend distribution tax)	-	-	-
<b>Total Finance Cost</b>	<b>15,704</b>	<b>1,929</b>	<b>1,431</b>

## ARUNJYOTI BIO VENTURES LIMITED

### Note 27 Depreciation and Amortisation Expenses

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Depreciation on plant, property and equipment	-	-	-
Depreciation on Investment properties	-	-	-
Amortisation on Intangible assets	-	-	-
<b>Total depreciation and Amortisation expenses</b>	<b>-</b>	<b>-</b>	<b>-</b>

### Note 28: Other expenses

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Audit Fees	1,00,000	1,00,000	50,000
Advertisement & Business Promotion Expenses	33,800	41,327	71,974
Insurance Charges	5,901	-	-
Repairs & Maintenance	-	-	-
Share Holders Service & Maintenance Charges	53,711	-	-
Stock Exchange Listing Charges	3,75,028	3,77,740	33,740
Travelling & Conveyance Expenses	-	7,20,313	4,07,488
ROC Charges	-	-	-
Printing & Stationery	15,500	896	33,569
Rent	-	57,600	2,01,600
Telephone Expense	1,967	22,433	18,796
Freight Charges	22,12,846	-	-
Other General Expenses	-	90,748	59,267
Import Expenses	2,62,828	-	-
Electricity Charges	-	1,626	1,228
Commission/Brokerage charges	-	45,000	25,000
Office Maintenance	-	1,200	7,517
Professional and Consultancy	2,38,750	1,90,420	1,15,800
Turnover Discount	-	57,42,860	-
Interest on TDS & Income Tax	43,176	15,557	-
Rates & Taxes	3,15,915	3,64,163	919
TA & DA Expenses	30,000	-	-
<b>Total</b>	<b>36,89,422</b>	<b>77,71,883</b>	<b>10,26,898</b>

### 28.1 Payment to Auditors

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
As An Auditor			
- Audit Fees	1,00,000	1,00,000	50,000
- Tax Audit	-	-	-
- Limited Review	-	-	-
In Other Capacity			
- Taxation Matters	-	-	-
- Company Law matters	-	-	-
- Certification matters	-	-	-
- Reimbursement of Expenses	-	-	-
<b>Total Payment to Auditor</b>	<b>1,00,000</b>	<b>1,00,000</b>	<b>50,000</b>

### 28.2 Corporate Social Responsibility( CSR) Not Applicable to this period

Particulars	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
Amount required to be spent as per Section 135 of the Companies Act, 2013	-	-	-
Amount spent during the year on:	-	-	-
		-	-

## ARUNJYOTI BIO VENTURES LIMITED

### 29. Related Party Disclosures (Ind AS 24):

Related Party disclosures required as per Accounting Standard (Ind AS-24) on "Related Party disclosures" issued by the Institute of Chartered Accountants of India, are as below:

#### a) Names of related parties and the Description of Relationship:

S. No	Name	Relationship
(i)	<b>Subsidiary companies</b>	<b>Nil</b>
(ii)	<b>Key Management Personnel &amp; Directors</b>	
	Venkatarama Rao Polsani	Director
	Pabbathi Praveen Kumar	Wholetime Director
	Manda Aditya Vardhan Reddy	Director
	Vanaja Kumari Dokiparthi	Director
	Babulal Raja Kumar	Wholetime Director
	Konadari Chandra Shekar	Director

#### b) Related Party Transactions during the year:

Name	Relationship with the company	Nature of Transaction	Value of Transaction
Pabbathi Praveen Kumar	Whole Time Director	Director Remuneration	Rs. 6,00,000

## ARUNJYOTI BIO VENTURES LIMITED

### 30. Consolidated and Separate Financial Statement (Ind AS 27):

The company has no subsidiary companies for the current reporting period. Hence consolidate and separate financial statement are not applicable.

### 31. Investments in Associates (Ind AS 28):

The company has not made any investments in any of its associates during the reporting period. This accounting standard has no financial impact on the financial statements for the current reporting period.

### 32. Interest in Joint Ventures (Ind AS 31):

The company has no interest in any Joint ventures. This accounting standard has no financial impact on the financial statements for the current reporting period.

### 33. Derivative instruments and un-hedged foreign currency exposure:

- a) There are no outstanding derivative contracts as at March 31, 2021 and March 31, 2020.
- b) Particulars of Un-hedged foreign currency exposure is: Nil

### 34. Secured Loans:

There are no Secured loans for the reporting period.

### 35. Confirmation of Balances:

Confirmation letters have been issued by the company to Trade Receivables, Trade Payables, Advances to suppliers and others advances requesting that the confirming party responds to the company only if the confirming party disagrees with the balances provided in the request and however the company has not received any letters on disagreements.

### 36. Net Current Assets:

S. No	Particulars	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
<b>A</b>	<b>Current Assets:</b>		
1	Inventories	2,59,478	2,96,484
2	Trade Receivables	1,83,81,369	2,67,25,481
3	Cash and Cash equivalent	80,87,045	1,11,76,399
4	Loans	-	-
5	Other Current Asset	53,33,981	58,24,519
	<b>Total Current Assets</b>	<b>3,20,61,873</b>	<b>4,40,22,882</b>
<b>B</b>	<b>Current Liabilities:</b>		
1	Borrowings	-	-
2	Trade Payables	1,31,03,211	2,18,42,239
3	Other Current Liabilities	1,42,39,491	1,81,34,003
4	Short term provisions	2,39,838	2,25,294
5	Current Tax Liability	-	-
	<b>Total Current liabilities</b>	<b>2,75,82,540</b>	<b>4,02,64,561</b>
<b>C</b>	<b>Current Assets-Current Liabilities</b>	<b>44,79,333</b>	<b>38,21,346</b>

---



---

## ARUNJYOTI BIO VENTURES LIMITED

---

### 37. Revenue from Operations:

S. No	Particulars	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
1	Sale of goods:		
	Sale of Manufactured Products	5,51,28,875	7,30,88,613
	Stock in trade	-	-
	Total	-	-
2	Revenue from Sale of Service	-	-
3	Other Operating Revenues	-	-

### 38. Revenue Reconciliation:

S. No	Particulars	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
1	Sale of Products"		
	Domestic	5,51,28,875	7,46,71,281
	Exports	-	-
	Gross Revenue	5,51,28,875	7,46,71,281
	Less: Discount	-	-
	Less: Returns	-	15,82,668
	Less: price Concession	-	-
	Less Incentives and Performance bonus	-	-
	Less: Goods and service Tax	-	-
	Net Revenues recognized from contracts with customers	5,51,28,875	7,30,88,613

### 38. Revenue Reconciliation:

S. No	Particulars	As at 31 <sup>st</sup> March 2021	As at 31 <sup>st</sup> March 2020
1	Interest on Deposits with With banks and Others.	-	-

## ARUNJYOTI BIO VENTURES LIMITED

40.

**a) Basic Earnings Per Share (continued operations):**

There are no discontinued operations hence, EPS is presented for continued operations only.

(Amount in Rs.)

Particulars	Year ended March 31, 2021	Year ended March 31, 2020
Nominal Value of Equity Shares (Rupees per Share fully paid-up) (A)	10	10
Profit after Tax (in Rs.) (B)	6,57,987	10,20,718
No of Shares outstanding as on 01.04.2020	20,70,900	20,70,900
Shares Issued During the Year	-	-
Weighted average number of Equity shares outstanding at the end of the year (C)	20,70,900	20,70,900
Earnings Per Share (in Rs.) – Basic (D = B÷C)	0.32	0.49

**b). Diluted earnings per share (continued operations):**

There are no discontinued operations hence, EPS is presented for continued operations only.

(Amount in Rs.)

Particulars	Year ended March 31, 2021	Year ended March 31, 2020
Nominal Value of Equity Shares (Rupees per Share fully paid-up) (A)	10	10
Profit after Tax (in Rs.) (B)	6,57,987	10,20,718
No of Shares outstanding as on 01.04.2020	20,70,900	20,70,900
Shares Issued During the Year	-	-
Weighted average number of Equity shares outstanding at the end of the year (C)	20,70,900	20,70,900
Dilutive Shares (D)	NIL	NIL
Earnings Per Share (in Rs.) – Diluted (E) (E = B÷C)	0.32	0.49

**41. Details of Loans given, Investments made and Guarantee given covered Under Section 186(4) of the Companies Act, 2013.**

The company has not extended any Corporate Guarantees in respect of loans availed by any company/firm as at March 31, 2021

## ARUNJYOTI BIO VENTURES LIMITED

### 42. Auditors' Remuneration:

(Amount in Rs.)

Particulars	March 31, 2021	March 31, 2020
Fees towards*		
Statutory Audit	1,00,000	1,00,000

\*The fees is exclusive of GST

### 43. Dues to Micro Small and Medium Enterprises:

Disclosure required as per section 22 of the Micro, Small and Medium Enterprise Development Act, 2006 (MSMED Act.) as at 31.03.2021.

SL No	Description	March 31, 2021
1	Principal amount due to suppliers under MSMED	NIL
2	Interest accrued and due to suppliers covered under MSMED on the above amount, unpaid	NIL
3	Payment made to suppliers (with Interest) beyond the appointed day during the year.	NIL
4	Payment made to suppliers (other than interest) beyond the appointed day during the previous year	NIL
5	Interest paid to suppliers covered under MSMED	NIL
6	Interest due & Payable to suppliers covered under MSMED Act., towards payments already made.	NIL

The information has been given in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with company.

### 44. Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

### 45. Credit Risk

Credit risk refers to the risk that counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

---

---

## ARUNJYOTI BIO VENTURES LIMITED

---

---

The company makes an allowance for doubtful debts/advances using expected credit loss model.

### 46. Liquidity risk

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company's exposure to liquidity risk is minimal as the promoters of the company is infusing the funds based on the requirements.

### 47. Amounts have been rounded off to nearest Rupee.

### 48. Notes 3 to 47 forms part of Balance Sheet and have been authenticated

For V Ravi & Co.,  
Chartered Accountants  
Firm Reg No:006492S

Ramesh Kumar D  
Partner  
Membership No: 217139  
UDIN: 21217139AAAAFA4442

Place: Hyderabad  
Date : 26.06.2021

For and on behalf of the Board of Directors  
Arunjyoti Bio Ventures Limited

Sd/-  
Pabbathi Praveen Kumar  
Wholetime Director & CFO  
DIN:02009879

Sd/-  
Babulal Raja Kumar  
Wholetime Director  
DIN:07529064

Sd/-  
Swati Jain  
Company Secretary & Compliance Officer